Tipepidine has recently garnered interest as a potential [[psychiatric drug]]. It is being investigated in [[major depressive disorder|depression]],<ref name="KawauraOgata2009" /><ref name="KAWAURAHONDA2010">{{cite journal|last1=KAWAURA|first1=Kazuaki|last2=HONDA|first2=Sokichi|last3=SOEDA|first3=Fumio|last4=SHIRASAKI|first4=Tetsuya|last5=TAKAHAMA|first5=Kazuo|title=A Novel Antidepressant-like Action of Drugs Possessing GIRK Channel Blocking Action in Rats|journal=Yakugaku Zasshi|volume=130|issue=5|year=2010|pages=699–705|issn=0031-6903|doi=10.1248/yakushi.130.699}}</ref><ref name="pmid24833905">{{cite journal | vauthors = Sasaki T, Hashimoto K, Tachibana M, Kurata T, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M | title = Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study | journal = Neuropsychiatr Dis Treat | volume = 10 | issue = | pages = 719–22 | year = 2014 | pmid = 24833905 | pmc = 4015794 | doi = 10.2147/NDT.S63075 | url = }}</ref> [[obsessive-compulsive disorder]],<ref name="HondaKawaura2011">{{cite journal|last1=Honda|first1=Sokichi|last2=Kawaura|first2=Kazuaki|last3=Soeda|first3=Fumio|last4=Shirasaki|first4=Tetsuya|last5=Takahama|first5=Kazuo|title=The potent inhibitory effect of tipepidine on marble-burying behavior in mice|journal=Behavioural Brain Research|volume=216|issue=1|year=2011|pages=308–312|issn=0166-4328|doi=10.1016/j.bbr.2010.08.010|pmid=20713091}}</ref> and [[attention-deficit hyperactivity disorder]] (ADHD).<ref name="pmid24493927">{{cite journal | vauthors = Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M | title = Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study | journal = Neuropsychiatr Dis Treat | volume = 10 | issue = | pages = 147–51 | year = 2014 | pmid = 24493927 | pmc = 3908907 | doi = 10.2147/NDT.S58480 | url = }}</ref><ref name="HashimotoSasaki2014">{{cite journal|last1=Hashimoto|first1=K.|last2=Sasaki|first2=T.|title=Old drug tipepidine as new hope for children with ADHD|journal=Australian & New Zealand Journal of Psychiatry|volume=49|issue=2|year=2014|pages=181–182|issn=0004-8674|doi=10.1177/0004867414553952}}</ref> Through inhibition of GIRK channels, tipepidine increases [[dopamine]] levels in the [[nucleus accumbens]], but without increasing [[hyperactivity|locomotor activity]] or producing [[methamphetamine]]-like [[behavioral sensitization]], and this action appears to be at least partly responsible for its [[antidepressant]]-like effects in rodents.<ref name="pmid23896570">{{cite journal | vauthors = Hamasaki R, Shirasaki T, Soeda F, Takahama K | title = Tipepidine activates VTA dopamine neuron via inhibiting dopamine D₂ receptor-mediated inward rectifying K⁺ current | journal = Neuroscience | volume = 252 | issue = | pages = 24–34 | year = 2013 | pmid = 23896570 | doi = 10.1016/j.neuroscience.2013.07.044 | url = }}</ref><ref name="pmid25687844">{{cite journal | vauthors = Hamao K, Kawaura K, Soeda F, Hamasaki R, Shirasaki T, Takahama K | title = Tipepidine increases dopamine level in the nucleus accumbens without methamphetamine-like behavioral sensitization | journal = Behav. Brain Res. | volume = 284| issue = | pages = 118–24| year = 2015 | pmid = 25687844 | doi = 10.1016/j.bbr.2015.02.012 | url = }}</ref>
